The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

Malaria is a global infectious disease that remains a leading cause of morbidity and mortality
in the developing world. Multiple environmental and host and parasite factors govern the …

Malaria transmission-blocking vaccines (TBVs) reduce disease transmission by breaking the
continuous cycle of infection between the human host and the mosquito vector. Domain 1 …

Infection with Plasmodium can elicit antibodies that inhibit parasite survival in the mosquito,
when they are ingested in an infectious blood meal. Here, we determine the transmission …

A malaria vaccine that blocks parasite transmission from human to mosquito would be a
powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in …

Malaria vaccine development has rapidly advanced in the past decade. The very first phase
3 clinical trial of the RTS, S vaccine was completed with over 15,000 African infants and …

Development of a Plasmodium falciparum (Pf) transmission blocking vaccine (TBV) has the
potential to significantly impact malaria control. Antibodies elicited against sexual stage …

An effective malaria vaccine remains a global health priority and vaccine immunogens
which prevent transmission of the parasite will have important roles in multi-component …

Malaria control relies heavily on the use of anti-malarial drugs and insecticides against
malaria parasites and mosquito vectors. Drug and insecticide resistance threatens the …

Introduction: Malaria is a devastating vector-borne disease caused by the Plasmodium
parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life …